- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03826030
Transcranial Direct Current Stimulation for Post-stroke Motor Recovery (TRANSPORT 2)
March 5, 2024 updated by: Duke University
TRANScranial Direct Current Stimulation for POst-stroke Motor Recovery - a Phase II sTudy (TRANSPORT 2)
This research study is to find out if brain stimulation at different dosage level combined with an efficacy-proven rehabilitation therapy can improve arm function.
The stimulation technique is called transcranial direct current stimulation (tDCS).
The treatment uses direct currents to stimulate specific parts of the brain affected by stroke.
The adjunctive rehabilitation therapy is called "modified Constraint-Induced Movement Therapy" (mCIMT).
During this therapy the subject will wear a mitt on the hand of the arm that was not affected by a stroke and force to use the weak arm.
The study will test 3 different doses of brain stimulation in combination with mCIMT to find out the most promising one.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
129
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wayne Feng, MD
- Phone Number: (919) 681-1700
- Email: wayne.feng@duke.edu
Study Contact Backup
- Name: Gottfried Schlaug, MD
- Email: Gottfried.Schlaug@baystatehealth.org
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- Active, not recruiting
- University of Alabama
-
-
California
-
Los Angeles, California, United States, 90089
- Completed
- University of California Los Angeles
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- MedStar National Rehabilitation Hospital
-
Contact:
- Margot Giannetti
- Phone Number: 202-877-1071
- Email: margot.giannetti@medstar.net
-
Principal Investigator:
- Richard D Zorowitz, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- Susan Murphy
- Phone Number: 404-712-1928
- Email: smurph7@emory.edu
-
Principal Investigator:
- Michael R Borich, PhD
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- Completed
- University of Kentucky
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01199
- Recruiting
- Baystate Medical Center
-
Principal Investigator:
- Gottfried Schlaug, MD
-
Contact:
- Abraham Madjidov, BS
- Phone Number: 413-794-9565
- Email: Abraham.Madjidov@baystatehealth.org
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Contact:
- Tato Sokhadze, PhD
- Phone Number: 919-684-3801
- Email: estate.sokhadze@duke.edu
-
Principal Investigator:
- Jody Feld, PhD, PT
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati
-
Contact:
- Colin Drury
- Phone Number: 314-753-5654
- Email: drurycd@ucmail.uc.edu
-
Principal Investigator:
- Oluwole Awosika, MD
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Cleveland VA Medical Center
-
Principal Investigator:
- Svetlana Pundik, MD
-
Contact:
- Ahlam Salameh
- Phone Number: 330-203-1918
- Email: ais20@case.edu
-
-
Pennsylvania
-
Elkins Park, Pennsylvania, United States, 19027
- Recruiting
- Moss Rehabilitation Research Institute
-
Contact:
- Sapna Kumar
- Phone Number: 215-663-6702
- Email: KumarSap@einstein.edu
-
Principal Investigator:
- Dylan Edwards, PT,PhD
-
Principal Investigator:
- Ning Cao, MD
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center
-
Contact:
- Jason Weimer
- Email: weimerjm@upmc.edu
-
Contact:
- Amy Boos
- Email: amy.boos@pitt.edu
-
Principal Investigator:
- George Wittenberg, MD
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Principal Investigator:
- Chris Gregory, PhD, PT
-
Contact:
- Valerie Salisbury
- Email: eichvr@musc.edu
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas Health Science Center / TIRR Memorial Hermann
-
Contact:
- Emily Stevens
- Phone Number: 713-500-7914
- Email: emily.a.stevens@uth.tmc.edu
-
Principal Investigator:
- Gerard Francisco, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Each subject must meet all of the following criteria to participate in this study:
- 18-80 years old; and
- First-ever unihemispheric ischemic stroke radiologically verified and occurred within the past 30-180 days; and
- >10° of active wrist extension, >10° of thumb abduction/extension, and > 10° of extension in at least 2 additional digits; and
- Unilateral limb weakness with a Fugl-Meyer Upper Extremity score of ≤ 54 (out of 66) to avoid ceiling effects; and
- An absolute difference of FM-UE scores between the two baseline assessments that is ≤ 2 points indicating stable motor impairment; if subject is not stable, then he/she will be invited for a reassessment after 7-14 days (but no more than 3 reassessments); and
- Pre-stroke mRS ≤2; and
- Signed informed consent by the subject or Legally Authorized Representative (LAR).
Each Subject who meets any of the following criteria will be excluded from the study:
- Primary intracerebral hematoma, subarachnoid hemorrhage or bi-hemispheric or bilateral brainstem ischemic strokes;
- Medication use at the time of study that may interfere with tDCS, including but not limited to carbamazepine, flunarizine, sulpiride, rivastigmine, dextromethorphan;
- Other co-existent neuromuscular disorders (pre- or post-stroke) affecting upper extremity motor function;
- Other neurological disorders (pre- or post-stroke) affecting subject's ability to participate in the study;
- Moderate to severe cognitive impairment defined as Montreal Cognitive Assessment (MOCA) score < 18/30;
- History of medically uncontrolled depression or other neuro-psychiatric disorders despite medications either before or after stroke that may affect subject's ability to participate in the study;
- Uncontrolled hypertension despite medical treatment(s) at the time of randomization, defined as SBP≥185 mmHg or DBP≥110 mmHg (patient can be treated, reassessed and randomized later);
- Presence of any MRI/tDCS/TMS risk factors including but not limited to: 8a) an electrically, magnetically or mechanically activated metallic or nonmetallic implant including cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system; 8b) a non-fixed metallic part in any part of the body, including a previous metallic injury to eye; 8c) pregnancy (effects of MRI, TMS, and tDCS on the fetus are unknown); 8d) history of seizure disorder or post-stroke seizure; 8e) preexisting scalp lesion under the intended electrode placement or a bone defect or hemicraniectomy;
- Planning to move from the local area within the next 6 months;
- Life expectancy less than 6 months;
- Has received Botulinum toxin injection to the affected upper extremity in the past 3 months prior to randomization or expectation that Botulinum will be given to the Upper Extremity prior to the completion of the last follow-up visit;
- Concurrent enrollment in another investigational stroke recovery study;
- Doesn't speak sufficient English to comply with study procedures;
- Expectation that subject cannot comply with study procedures and visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Sham tDCS + mCIMT
Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
|
sham group receives no active current stimulation except 15 seconds of current ramp up in the beginning and 15 seconds of current ramp up in the end of the 30-minute session to create a scalp perception to blind the subject.
All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
|
Active Comparator: 2 mA tDCS + mCIMT
2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
|
All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
|
Active Comparator: 4 mA + mCIMT
4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
|
All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change of Motor Impairment as Assessed by Fugl-Meyer Upper-Extremity (FM-UE) scale
Time Frame: Baseline through day 15 (after the intervention) and follow-up at day 45 and 105
|
The Fugl-Meyer Upper-Extremity (FM-UE) scale is a measure of motor impairment.
FM-UE scale consists of a 33-item assessment which provides a global assessment of UE motor impairment.
A rater observes 30 voluntary UE motions and 14 voluntary lower extremity (LE) motions, 6 tendon tap responses, and provides an ordinal rating (2=near normal ability/response, 1=partial ability, 0=unable to perform/no response).
FM-UE scale is a proven scale with excellent intra-rater reliability (0.99), inter-rater reliability (0.99), test-retest reliability (0.94 -0.99), and internal consistency (0.97).
|
Baseline through day 15 (after the intervention) and follow-up at day 45 and 105
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change of Functional Motor Activity as assessed by Wolf Motor Function Test (WMFT)
Time Frame: Baseline through day 15 (after the intervention) and follow-up at day 45 and 105
|
The Wolf Motor Function Test (WMFT) is a measure of functional motor activity that quantifies upper extremity (UE) motor ability through timed and functional tasks.
The WMFT consists of approximately 17 functional, strength and movement quality tasks.
Each task is rated on a 6 point scale.
Lower scores on the 6 point scale indicate lower functioning levels (1 = does not attempt with UE being tested, 2= UE being tested does not participate functionally, but an attempt is made to use the UE, 3= Does attempt but requires assistance of the UE not being tested, requires more than 2 attempts to complete, 4= Does attempt but may lack precision, fine coordination or fluidity, 5= Does attempt, movement similar to non-affected side but slightly slower, and 6= Does attempt and movement appears to be normal).
|
Baseline through day 15 (after the intervention) and follow-up at day 45 and 105
|
Mean Change of Patient Centered Quality of Life as Assessed by Stroke-Impact-Scale(SIS) hand subscale
Time Frame: Baseline through day 15 (after the intervention) and follow-up at day 45 and 105
|
The SIS hand subscale assesses how having a stroke impacts a patient's life.
The SIS has 8 subscales which ask questions regarding a patient's physical limitations, memory and thinking, emotions and mood, ability to communicate, daily activities, mobility at home and in the community, use of hand most affected by stroke, and ability to participate in meaningful life activities.
Each subscale item is rated on a scale from 5-1 (5= None of the time, 4=a little of the time, 3=Some of the time, 2=Most of the time, 1=All of the time)
|
Baseline through day 15 (after the intervention) and follow-up at day 45 and 105
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wayne Feng, MD, Duke University
- Principal Investigator: Gottfried Schlaug, MD, PhD, Baystate Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2019
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
January 30, 2019
First Submitted That Met QC Criteria
January 30, 2019
First Posted (Actual)
February 1, 2019
Study Record Updates
Last Update Posted (Estimated)
March 6, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00103316
- 7U01NS102353-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
We will follow the National Institute of Health Stroke Trial Network policy and procedure to share IPD.
Please refer to https://nihstrokenet.org/ for detailed information.
IPD Sharing Time Frame
Please refer to https://nihstrokenet.org/ for detailed information in term of time-frame of sharing such data
IPD Sharing Access Criteria
Please refer to https://nihstrokenet.org/ for detailed information in term of time-frame of sharing such data
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Ischemic
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Sham
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Instituto Mexicano del Seguro SocialInstituto Nacional de Salud Publica, Mexico; Universidad Nacional Autonoma... and other collaboratorsRecruitingEffect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy (EA&DPN)Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | Acupuncture | Diabetic Polyneuropathy | Electroacupuncture | Nerve ConductionMexico
-
University of LeipzigReCor Medical, Inc.RecruitingHeart Failure With Preserved Ejection Fraction | Hypertension, RenalGermany
-
Institut National de la Santé Et de la Recherche...Centre Hospitalier Régional Universitaire MontpellierCompletedChronic Obstructive Pulmonary Disease
-
Corporacion Parc TauliCompletedFatigue | Inflammatory Bowel DiseaseSpain
-
Oulu University HospitalLoisto Terveys, Oulu; Fysios Kastelli, Oulu; Faskia-Markus, OuluEnrolling by invitationLow Back Pain | Low Back Pain, RecurrentFinland
-
Medical University of South CarolinaCompletedUse of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)Upper Respiratory InfectionUnited States
-
Istituto Superiore di Osteopatia di MilanoCompletedHealthy | Osteopathic ManipulationItaly
-
Phramongkutklao College of Medicine and HospitalUnknownIschemic Reperfusion InjuryThailand